Cambridge, Massachusetts, USA, May 22, 2026
Agios Pharmaceuticals has announced that the European Commission (EC) has granted marketing authorization for PYRUKYND® (mitapivat) for the treatment of anemia in adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. The approval represents a major advancement in rare blood disorder treatment and makes PYRUKYND the only medicine approved across the European Union for this broad thalassemia patient population.
The milestone significantly expands Agios’ global hematology portfolio and strengthens the company’s leadership position in rare disease therapeutics. The approval follows earlier authorizations in the United States, Saudi Arabia, and the United Arab Emirates, further accelerating the international commercialization of the oral therapy. Agios confirmed that Avanzanite Bioscience B.V. will continue managing the commercialization and distribution of PYRUKYND across Europe under an existing strategic partnership.
Phase 3 Trials Show Significant Clinical Benefits
The European Commission decision was based on positive findings from the global ENERGIZE and ENERGIZE-T Phase 3 clinical trials, which evaluated the safety and efficacy of mitapivat in adults living with alpha- or beta-thalassemia. The randomized, double-blind, placebo-controlled studies included both transfusion-dependent and non-transfusion-dependent patient populations.
The ENERGIZE trial focused on patients with non-transfusion-dependent thalassemia and evaluated improvements in hemoglobin levels, fatigue reduction, and overall quality of life. Meanwhile, the ENERGIZE-T study assessed the therapy’s ability to reduce blood transfusion requirements in transfusion-dependent patients. According to Agios, the studies demonstrated clinically meaningful benefits, supporting the therapy’s potential to reduce disease burden across a broad range of thalassemia patients regardless of genotype or transfusion status.
Advertisement
Medical experts involved in the studies described the approval as a major advancement for the global thalassemia community, particularly because treatment options for patients have historically been limited. Researchers emphasized that the oral therapy could improve long-term disease management while helping reduce complications associated with chronic anemia and frequent transfusions.
PYRUKYND functions as an oral pyruvate kinase activator, targeting the underlying metabolic dysfunction associated with anemia. By improving red blood cell energy production and function, the medicine aims to address the core biological mechanisms contributing to thalassemia-related anemia.
Rare Blood Disorder Innovation Expands Globally
Thalassemia is a rare inherited blood disorder that affects the body’s ability to produce normal hemoglobin, leading to chronic anemia, fatigue, organ complications, reduced quality of life, and shortened life expectancy. The disease affects thousands of patients globally and remains a major healthcare burden in several regions across Europe, the Middle East, and Asia.
Agios stated that the latest European approval reflects growing international recognition of PYRUKYND’s therapeutic potential and reinforces the company’s commitment to transforming treatment options for rare hematologic diseases. Industry observers believe the approval could significantly strengthen Agios’ commercial position within the rare disease market while increasing competition in the evolving hematology therapeutics sector.
The company also highlighted the importance of strategic partnerships in expanding access to innovative therapies across international markets. Through its collaboration with Avanzanite Bioscience, Agios plans to accelerate patient access to PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland.
Healthcare organizations supporting thalassemia patients welcomed the approval, describing it as a meaningful step toward improving disease outcomes and reducing the long-term physical and emotional burden experienced by patients and families. Experts believe the approval may also encourage broader adoption of targeted metabolic therapies within hematology and rare disease medicine.
As precision medicine continues reshaping the pharmaceutical landscape, Agios’ latest regulatory milestone demonstrates the increasing importance of innovative oral therapies designed to address the underlying biology of complex rare disorders.
Source: Agios Pharmaceuticals press release
